Sign inJoin waitlistJoin the waitlist

Charles Redfern

Physician · OneOncology

Credentials: · · · ·

History

OneOncology
Present

University of California-San Francisco
1995–1997
Internal Medicine
Johns Hopkins Hospital
1991–1994
Johns Hopkins Univ Sch of Med
1987–1991
Johns Hopkins University
1983–1987

Research

Sipuleucel-T immunotherapy for castration-resistant prostate cancer
New England Journal of Medicine · 2010 · 4,436 citations
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Journal of Clinical Oncology · 2006 · 897 citations
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Journal of Clinical Oncology · 2020 · 657 citations

HP
Haeseong Park
4 papers
IK
Ian Krop
4 papers
CH
Celestia Higano
3 papers
Eric Small
3 papers
Rashmi Murthy
3 papers
SM
Shanu Modi
3 papers
AM
Alvaro Moreno-Aspitia
2 papers
AK
Andrew Kwa
2 papers
FV
Frank Valone
2 papers
Fred Rosenfelt
2 papers
Glenn Fishman
2 papers
Michael Gordon
2 papers

Clinical trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2023–2030
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2021–2027
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
Site PI · Unknown · Phase 2
Xcyte Therapies
2004